(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Ringleader of suspected human trafficking network arrested in Ethiopia - 2Your big brain makes you human – count your neurons when you count your blessings
- 3Eurovision Song Contest changes voting rules after controversial allegations against Israel
- 4Distributed storage Answers for Information Reinforcement
- 5The Most Compelling Books of the 10 years
- Becoming Familiar with an Unknown dialect: My Language Learning Excursion
- Become the best at Discussion: 6 Procedures for Progress
- US FDA unveils new pathway to approve personalized therapies
- NASA's Artemis II launch leaves Americans in awe: 'We're going back to the frickin' moon!'
- A Timeline of Rising Antisemitism in Australia
- Surging measles cases are 'fire alarm' warning that other diseases could be next
- Was it a stone tool or just a rock? An archaeologist explains how scientists can tell the difference
- 6 Arranging Administrations to Change Your Open air Space
- Portable Installment Answers for Independent ventures
